Posted by SLS on November 7, 2000, at 16:43:26
In reply to Re:ATTENTION ANERGIC DEPRESSION SUFFERERS/Scott, posted by Anna P. on November 7, 2000, at 14:42:59
Hi Anna.
Thanks for replying.
I had always known viloxazine as a NE reuptake inhibitor. When I reviewed the Medline database, I could not find anything that would contradict this, although there may be some variabilitly in the conclusions of its relative potency.
I am still intrigued by your choice. What led you to choose viloxazine? I would definitely be interested in trying it given your results with it. For some reason, I recall a post stating that it is no longer being manufactured. Do you know anything about it? What countries currently market this drug? I'm pretty sure France had.
Thanks again.
- Scott
---------------------------------------------------------: Acta Psychiatr Scand Suppl 2000;402:28-36
Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy.
Humble M
Division of Psychiatry, Karolinska Institutet, Huddinge University Hospital,
Sweden.[Medline record in process]
Imipramine and other subsequently developed antidepressants produce numerous neurochemical effects, some of which presumably represent active antidepressant principles. Numerous studies have compared the efficacy of selective serotonin reuptake inhibitors (SSRIs) with noradrenaline reuptake inhibitors (NRIs) with variable selectivity, such as desipramine, lofepramine, viloxazine, maprotiline or oxaprotiline. Most studies have failed to show differences in response rates or subtype responsivity. However, in some studies NRIs appear to be superior to SSRIs as regards retardation and, conversely, SSRIs appear superior as regards anxiety symptoms. Furthermore, NRIs may be more effective than SSRIs in severe depression. The novel selective NRI reboxetine has been shown to be at least as effective as imipramine, desipramine and fluoxetine in the treatment of major depression. Moreover, reboxetine may also improve social functioning significantly more than fluoxetine providing a better quality of the remission.
PMID: 10901156, UI: 20356317
--------------------------------------------------------------4: Psychopharmacology (Berl) 1995 Sep;121(2):173-9
The additive effects of quinine on antidepressant drugs in the forced swimming test in mice.
Guo WY, Todd KG, Bourin M, Hascoet M
Laboratoire de Pharmacologie et GIS Medicament, Faculte de Medicine, Universite de Nantes, France.
The aim of this study was to investigate if quinine plus antidepressant drugs (ADS) leads to an additive effect in the forced swimming test. Quinine (0.125, 0.5 mg/kg) and ADS (subactive doses) were given IP 45 and 30 min, respectively, before the test. When combined with QUIN, all drugs that act via inhibition of 5-HT uptake (imipramine, amitriptyline, citalopram, paroxetine, fluoxetine and fluvoxamine) significantly increased the swimming time of mice. Among trazodone, mianserin and iprindole (atypical ADS), only iprindole combined with quinine decreased the immobility (increased swimming) of the animals. The specific noradrenaline (NA) uptake inhibitors, desipramine and viloxazine, but not maprotiline, were also found to reduce the immobility time when pretreated with quinine. The mixed monoamine oxidase (MAO) inhibitor (pargyline) and MAO-A inhibitor (moclobemide) also shortened the period of immobility whereas the MAO-B inhibitor (nialamide) and the dopamine (DA) uptake inhibitor (bupropion) did not. Quinine's additive effects on several types of ADS is likely a result of blockade of potassium channels.
PMID: 8545522, UI: 96117729
poster:SLS
thread:48258
URL: http://www.dr-bob.org/babble/20001102/msgs/48387.html